insights_auto
Hvorfor har KYNB gått opp? 8,87%?
GÃ¥ mer i dybdenchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
5,28Â USD
arrow_upward
+8,87%(+0,43) 1Â D
19. okt., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for KYNB …
Ã…pne
5,08Â USD
Høy
5,29Â USD
Lav
4,98Â USD
Markedsverdi
21,38Â mill.
Snittvolum
26,16k
Volum
0,00
P/E-forhold
0,12
52 u høy
9,70Â USD
52Â u lav
4,85Â USD
EPS
45,30Â USD
Beta
1,05
Utestående aksjer
4,05Â mill.
Antall ansatte
34
Ã…pne
5,08Â USD
Høy
5,29Â USD
Lav
4,98Â USD
Markedsverdi
21,38Â mill.
Snittvolum
26,16k
Volum
0,00
P/E-forhold
0,12
52 u høy
9,70Â USD
52Â u lav
4,85Â USD
EPS
45,30Â USD
Beta
1,05
Utestående aksjer
4,05Â mill.
Antall ansatte
34
Nyhetssaker
Fra nettkilder og nyhetspartnere
ad-hoc-news.de
·
for 2 døgn siden
Kyntra Bio stock fell to USD 4.85 on October 16, down 9.5 percent
Profil
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Om Kyntra Bio Inc
Administrerende direktør-
Ansatte34
Grunnlagt1. jan. 1993
HovedkontorSan Francisco, California, USA
Sektor-
Nettstedkyntrabio.com